» Articles » PMID: 36612263

The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up

Abstract

Postoperative deserved outcomes in acromegalic patients are to normalize serum insulin-like growth factor (IGF-1), reduce the tumoral mass effect, improve systemic comorbidities, and reverse metabolic alterations. Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. From 2006 to 2019, 394 patients affected by PitNET were intervened via endoscopic endonasal transsphenoidal approach by the same senior surgeon. A total of 44 patients that met the criteria to be diagnosed as acromegalic and were followed up at least for 24 months (median of 66 months (26-156) were included in the present study. Multiple predictive variables [age, gender, preoperative GH and IGF-1 levels, maximal tumor diameter, Hardy's and Knosp's grade, MRI. T2-weighted tumor intensity, cytokeratin expression pattern, and clinicopathological classification] were evaluated through uni- and multivariate statistical analysis. Sparse probability of long-term remission was related to younger age, higher preoperative GH and- or IGF-1, group 2b of the clinicopathological classification, and sparsely granulated cytokeratin expression pattern. Augmented recurrence risk was related to elevated preoperative GH levels, tumor MRI T2-weighted hyperintensity, and sparsely granulated cytokeratin expression pattern. Finally, elevated risk for reintervention was related to group 2b of the clinicopathological classification, Knosp's grade IV, and tumor MRI T2-weighted hyperintensity. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp's grade IV, MRI T2-weighted tumor hyperintensity and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET.

Citing Articles

Biochemical remission, diagnostic delays, and comorbidities of acromegaly in China: a large single-centre retrospective study.

Bai X, Duan L, Yang S, Wang T, Yao Y, Zhang M Front Endocrinol (Lausanne). 2025; 16:1526625.

PMID: 40065992 PMC: 11891042. DOI: 10.3389/fendo.2025.1526625.


Predictors of growth hormone level on postoperative day one in patients with acromegaly.

Li H, Li Z, Feng T, Chen Y, Zhong J, Wei L Endocrine. 2024; .

PMID: 39707075 DOI: 10.1007/s12020-024-04130-6.


Grading and staging for pituitary neuroendocrine tumors.

Villa C, Birtolo M, Perez-Rivas L, Righi A, Assie G, Baussart B Brain Pathol. 2024; 35(1):e13299.

PMID: 39182993 PMC: 11669418. DOI: 10.1111/bpa.13299.


[Unification of pathomorphological examination of patients with neuroendocrine tumors of the pituitary gland. Controversial issues of the new classification].

Pronin V, Antsiferov M, Alekseeva T, Pronin E, Lapshina A, Urusova L Probl Endokrinol (Mosk). 2024; 70(3):31-45.

PMID: 39069771 PMC: 11334236. DOI: 10.14341/probl13376.


Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy.

Kageyama K, Nishiyama M Cancers (Basel). 2023; 15(23).

PMID: 38067229 PMC: 10705121. DOI: 10.3390/cancers15235526.


References
1.
Wang Q, Guo X, Gao L, Wang Z, Deng K, Lian W . Surgical Outcome of Growth Hormone-Secreting Pituitary Adenoma with Empty Sella Using a New Classification. World Neurosurg. 2017; 105:651-658. DOI: 10.1016/j.wneu.2017.06.071. View

2.
Freda P, Bruce J, Reyes-Vidal C, Singh S, DeLeon Y, Jin Z . Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly. Pituitary. 2020; 24(2):170-183. PMC: 7969360. DOI: 10.1007/s11102-020-01094-4. View

3.
Freda P, Wardlaw S, Post K . Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg. 1998; 89(3):353-8. DOI: 10.3171/jns.1998.89.3.0353. View

4.
Cusimano M, Fenton R . The technique for endoscopic pituitary tumor removal. Neurosurg Focus. 1996; 1(1):e1. DOI: 10.3171/foc.1996.1.1.3. View

5.
Ku C, Kim E, Oh M, Lee E, Kim S . Surgical and endocrinological outcomes in the treatment of growth hormone-secreting pituitary adenomas according to the shift of surgical paradigm. Neurosurgery. 2012; 71(2 Suppl Operative):ons192-203. DOI: 10.1227/NEU.0b013e318265a288. View